Germantown, MD, February, 9, 2021 – Seraxis, a biotech company developing a cell replacement therapy for insulin-dependent diabetes today announced the successful closing of a $40M Series C private financing round. The financing was led by Eli Lilly and Company, with participation from Frazier Healthcare Partners, Polaris Ventures, JDRF T1D Fund, and other investors.
{iframe}https://seraxis.com/wp-content/uploads/2017/03/Seraxis-Press-Release_Feb-9-2021.pdf?utm_source=MCEDC+Newsletter&utm_campaign=7e9e7d0db8-EMAIL_CAMPAIGN_020921&utm_medium=email&utm_term=0_2ec33b29cd-7e9e7d0db8-84474257&mc_cid=7e9e7d0db8{/iframe}